You might like
🧬🛡️ HER2-low tumors escape HER2 ADCs by losing the target • True HER2 loss is uncommon in HER2-amplified disease but frequent in HER2-low, where HER2 isn’t oncogenic • On HER2 ADC therapy, ~50% of tumors reduce HER2; among reducers, ~half become IHC 0 • Reduced HER2 →…
Just out in @NEJM, the results of ASCENT-04, by @stolaney1 et al. Among patients with PD-L1+ mTNBC, first-line SG/pembro significantly improved PFS (11.2 vs 7.8 months, HR 0.65, p<0.001) compared with chemo/pembro. New standard of care for this population. nejm.org/doi/full/10.10…
Top #BreastCancer trials to watch ahead of @SABCSSanAntonio 2025, based on oncologists’ posts on 𝕏 — curated by @Larvol CLIN. Explore more insights and data from #SABCS25: t.ly/S9em7 #LARVOL #SABCS2025 #Oncology #CancerResearch #CancerData #Oncologylnsights…
<72hrs to #SABCS25, here is a📝 of 🔑 from #CommunityOncologists perspective. What’s on your radar? - #lidERA - #LORETTA - #NSABP42 - #EMBER3 - #evERA - #VIKTORIA1 - #ASCENT07 - #INSEMA - #HER2Climb05 - #PREFER #bcsm #OncTwitter @AACR @SABCSSanAntonio @OncoAlert
If you were still debating if osimertinib was better than gefitinib/Erlotinib: FLAURA OS update presented by @RamalingamMD at #ESMO19: MS OS 38.6 vs 31.8 mos, impressive 54% ⬇️ in CNS progression (HR 0.48), we still need better drugs for rare EGFR mutations and L858R. #lcsm
What after Osimertinib? Chemo? Not always! Many targetable fusions drive osi resistance, and more and more promising TKIs are emerging @OncoAlert #ESMO19
Resistance post osimertinib: acquired fusion in 16% of the NSCLC, all can be targeted (RET, FGFR3, BRAF, ALK)!! Much more fusions than reported because most studies at resistance are on ctDNA. 16% is what we find with RNAseq on a fresh tissue biopsy (n=31). 1526P #ESMO2019
Brilliant presentation on role of ctDNA in detecting molecular relapse for early stage breast cancer by Nick Turner 1. Biology of breast cancer determined at initial diagnosis 2. Lead time (10mos) prior to clinical relapse 3. Consistent findings across all subtypes #ESMO19 #bcsm
Very proud of @RamalingamMD for outstanding presentation of OS from FLAURA! Exciting data with over 3 yr OS for osimertinib and over 25% of patients still on at 3 years. Real hope for our patients with EGFRmut NSCLC but still much room to go.
Dr. Hoyle presents the results of STAMPEDE @Prof_Nick_James stratifying M1 patients between low/high risk (LATITUDE) and low/high volume (CHAARTED). Similar benefit across subgrups. #ESMO18
JAEVILIN Renal 101 preliminary results presented by Dr. Motzer. Double the ORR with Avelumab+Axitinib, and improved PFS. Overall population and PDL1 positive poliarquia with similar benefit. OS still premature. #ESMO18
SOLAR-1: Randomized Phase 3 Study of Alpelisib (alpha-specific PI3k- Inhibitor) + Fulvestrant vs Fulvestrant alone. Results: PI3k mutation +ve PFS: 5.7m vs 11.0 m. Tox: Increased hyperglycemia (36% Grade3/4) and rash (10% Grade 3) #ESMO18
New stantard of care(Abiraterone plus ADT) for M1 prostate cancer with at least 2 : gleason >= 8 , 3 or more bone lesions, visceral disease
New stantard of care(Abiraterone plus ADT) for M1 prostate cancer with at least 2 : gleason >= 8 , 3 or more bone lesions, visceral disease
7 year DFS 93.3% with Tolaney et al APT regimen of which 4 or 1% were distant. Very well tolerated and a new standard of care. #ASC017
Aleix Pratt great PD recommends rx for ESBC HER2. Moving fwd more not always better. #asco17
Agree. Currently TIL does not impact my clinical practice at all. #SABCS16
More data on TILs being associated w/ good prognosis in TNBC - not sure how to use in treatment decision-making however #sabcs16
Hard to know what to make of extended duration AI rx. Gnant summary. #sabcs2016
United States Trends
- 1. #SmackDown N/A
- 2. #DragRace N/A
- 3. Kit Wilson N/A
- 4. Olympics N/A
- 5. #TheLastDriveIn N/A
- 6. #OPLive N/A
- 7. UConn N/A
- 8. Pistons N/A
- 9. Obamas N/A
- 10. St. John N/A
- 11. #loveduringlockup N/A
- 12. Athena N/A
- 13. Brunson N/A
- 14. Mariah Carey N/A
- 15. Giulia N/A
- 16. Lion King N/A
- 17. Tiffany Stratton N/A
- 18. Myki N/A
- 19. Chelsea Green N/A
- 20. Braylon Mullins N/A
You might like
Something went wrong.
Something went wrong.